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Background: The concentration of steroid glucuronides in serial samples of
early morning urine (EMU) can be used to predict the fertile period in the female
menstrual cycle. The monoclonal antibody 4155 has been used as a convenient
means of measuring the concentration of steroid glucuronides in EMU, as it
specifically recognises the steroid hormone estrone b -D-glucuronide (E3G),
with very high affinity, and the closely related hormone estriol 3-(b -D-
glucuronide) (El3G), with reduced affinity. Although 4115 binds these
hormones with different affinities, EI3G differs from E3G only in the addition of
a hydroxyl group and reduction of an adjacent carbonyl. To investigate the
structural basis of this fine binding specificity, we have determined the crystal
structures of the variable fragment (Fv) of 4155 in complex with each of these
hormones. 
Results: Two crystal forms of the Fv4155–El3G complex, at resolutions of
2.1 Å and 2.5 Å, and one form of the Fv4155–E3G complex, at 2.1 Å resolution
were solved and refined. The crystal structures show the E3G or El3G antigen
lying in an extended cleft, running from the centre of the antibody combining
site down one side of the variable domain interface, and formed almost entirely
from residues in the heavy chain. The binding cleft lies primarily between the
heavy chain complementarity determining regions (CDRs), rather than in the
interface between the heavy and light chains. In both complexes the binding of
the glucuronic sugar, and rings A and B of the steroid, is specified by the shape
of the narrow cleft. Analysis of the Fv structure reveals that five of the six CDR
regions can be assigned to one of the predefined canonical structural classes.
Conclusions: The difference in the binding affinity of Fv4155 for the two
steroid hormones is accounted for by a subtle combination of a less favoured
hydrogen-bond geometry, and a minor rearrangement of the water molecule
network around the binding site. The rearrangement of water molecules results
from the burial of the additional hydroxyl group of the El3G in a hydrophobic
environment.
Introduction
The ability of an antibody to recognise an antigen with
high specificity and binding affinity provides a useful
model with which to investigate protein–ligand interac-
tions at the molecular level. Despite extensive studies of
antibody–antigen interactions, the structural features that
determine specificity, and the extent of cross-reactivity,
are often subtle and remain elusive. The work presented
here examines how differences in binding affinity can arise
from a small change in the bound ligand.
In recent years, a number of structures have been reported
of antibodies that bind to either steroid [1,2], carbohydrate
[3–5] or steroid-carbohydrate [6,7] ligands. These structures
have revealed that binding of such small antigens occurs
within hydrophobic clefts and pockets of the antibody,
which have high shape complementarity with the ligand.
Structural studies of the antibody DB3 bound to multiple
steroid ligands [2], and the crystal structures of the anti-
digoxin antibodies, 26-10 [6] and 40-50 [7], revealed that
the steroid moiety is inserted into a hydrophobic cleft in
the antigen-binding site. Comparison of 26-10 and 40-50
demonstrated that the antigen-binding fragments (Fabs)
of these antibodies bind their structurally-related ligands
in different orientations. Specific recognition of a particu-
lar ligand is enforced by both charged group complemen-
tarity and hydrogen-bond interactions. The binding of
digoxin by Fab 26-10, however, does not involve any
hydrogen bonds or salt bridges and the high binding affin-
ity and specificity displayed by this complex arises pri-
marily from shape complementarity. In addition, the im-
portance of the presence of aromatic amino acids around
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the antigen-binding site of antibodies has been demon-
strated [8,9]. The antibody Se155-4 binds a dodecasaccha-
ride in a binding site consisting of almost exclusively of aro-
matic amino acids [4], which form a complementary surface;
hydrogen bonds and hydrophobic interactions govern the
specificity. The role of a particular buried water molecule in
this complex was shown to be important; in addition to
being involved in four hydrogen bonds, the water molecule
enhances the Fab–antigen surface complementarity. 
We report here the high-resolution structures of a variable
(Fv) fragment, Fv4155, from a murine immunoglobulin
G1 with the k light chain complexed to two different, but
closely related, steroid hormone ligands: estrone b -D-glu-
curonide (E3G) and estriol 3-(b -D-glucuronide) (EI3G).
The affinity constants for the Fv4155 complexes with E3G
and El3G are approximately 108 and 107 l mol–1, respec-
tively. These values are 100-fold lower than those ob-
served for the intact monoclonal antibody 4155 (S Howell,
personal communication). The importance of monitoring
the levels of these steroid hormones to predict the female
fertile period has been demonstrated [10–12].  E3G and
El3G are principal urinary metabolites of estradiol, and
peak levels of both hormones usually occur in urine within
24 hours of the luteinising hormone (LH) surge [13],
which itself occurs 24–56 hours before ovulation [14].
The urinary levels of E3G have been found to be the most
consistent estrogen glucuronide marker for the onset of the
fertile period [10]. E3G and El3G both consist of a steroid
moiety linked to a glucuronic sugar at position 3 (Figure 1).
A range of these estrogen glucuronides have been identi-
fied, where the glucuronic acid moiety is combined with
the various different free hydroxyl groups of estrogens [15].
El3G differs from E3G only in the addition of a hydroxyl
group at position 16 and the reduction of the ring carbonyl
group to a hydroxyl at position 17. Although some estrogen
metabolism occurs in the intestine and kidneys, the liver is
responsible for the majority of estrogen metabolism, in-
cluding the conjugation with glucuronic acids.
The small differences in the closely related steroid hor-
mones, E3G and EI3G, provides an ideal opportunity to
investigate the basis of the fine specificity of antigen
recognition. The three-dimensional structure determina-
tion of Fv4155 complexed with these two different lig-
ands permits a detailed comparison of the atomic en-
vironment at the binding site, and an analysis of the
observed differences in the binding affinity of Fv4155 for
the two hormones.
Results and discussion
Overview of the structures
The general structure of the 4155 antibody Fv fragment is
typical of other Fvs (Figure 2). Three distinct crystallo-
graphic forms of the Fv–steroid hormone ligand complex
were obtained (Table 1): two different crystal forms of the
Fv4155–El3G complex (E13G-I and E13G-II), and one iso-
morphous structure of the Fv4155–E3G complex (E3G-I).
The Fv molecule is numbered according to the convention
of Kabat et al. [16] with the light and heavy chains desig-
nated by L and H, respectively. In all three crystal forms
the protein shows virtually no conformational changes, and
fitting of conserved framework residues between them
shows root mean square (rms) values close to the Luzzati
[17] estimated positional error for each complex (El3G-II
and E3G-I, 0.17Å; El3G-I, 0.22Å), as shown in Table 2.
When the two high-resolution P4212 structures (El3G-II
and E3G-I) are superimposed, using the Ca atoms from
both the light and heavy chains, including the six comple-
mentarity determining regions (CDRs) which determine
antigen specificity, the rms difference is only 0.17Å. The
fitting of the Fv4155–El3G Ca atoms of the light and heavy
chains in the two different space groups, however,  gives an
overall rms difference of 0.46Å. The higher rms difference
when fitting these Fvs is at least partly due to the lower res-
olution of El3G-I rather than genuine differences.
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Figure 1
Schematic representation of the steroid hormone ligands, showing the
numbering system used and the steroid nomenclature. (a) Estriol 3-(b -
D-glucuronide) (El3G). (b) Estrone b -D-glucuronide (E3G).
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Superposition of the Ca positions of residues equivalent to
those reported by Padlan [18], using the program ALIGN
[19], reveals that the VH and VL domains are related to
each other by a rotation of 176.2° and a translation of
–0.6Å  about a pseudo-twofold rotation axis. This rotation
and translation is within the range found by Padlan in a
comparison of murine and human antibodies. For all three
complexes, the VL and VH domains interact to bury ap-
proximately 15% (730Å2) and 14% (700Å2) of the solvent-
accessible surface area of the light and heavy chains,
respectively. Four of the six CDR loops, and the frame-
work residue Leu47H, of the antibody are in contact with
the steroid hormone ligand. According to the analysis of
Kabat et al. [16], leucine is rarely observed in position 47
of the heavy chain; this residue is normally tryptophan.
This is the first crystal structure of an antibody containing
a leucine residue at this position. No obvious advantages
of replacing tryptophan by leucine at 47H can be identi-
fied. The ligand interaction with Fv4155 involves hydro-
gen bonds and van der Waals interactions in a narrow cleft
that extends from the centre of the binding site down one
side of the VL and VH domain interface. All three com-
plexes show only slight conformational differences within
the protein itself, but the two different ligands bind in
slightly different conformations, with respect to each other,
within the Fv binding site.
Complementarity determining regions (CDRs)
The binding cleft is largely made up from the heavy chain
CDRs, with a minor contribution from the CDR L3 of the
light chain. The orientation of the CDRs is identical in
the binding of the two analogues with nearly all the inter-
actions between the ligand and Fv4155 being conserved.
Non-conserved interactions occur at the extra hydroxyl
group at position 16 of the cyclopentane ring D of El3G.
In all three complexes 19 of the 64 residues in the CDRs
make contact with the ligand. 
An early analysis of known immunoglobulin structures by
Chothia and Lesk [20,21] revealed only a small repertoire
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Figure 2
The overall fold of the Fv fragment, Fv4155.
(a) Stereoview of the Ca tracing of Fv4155.
The N and C termini and every tenth residue
are labelled for both the light (L; purple) and
heavy (H; green) chains; Ca positions are
marked by black spheres. (b) A ribbon
diagram of the Fv fragment Fv4155 in the
same orientation as (a). The VL and VH chains
are coloured purple and green, respectively.
The bound E3G molecule is shown in white
ball-and-stick representation. (Figures were
generated using the programs MOLSCRIPT
[51] and Raster3D [52].)
(a)
(b)
N
110H
10H
50L
110L
70H
C
90L
50H
C
90H
10L
70L
30L
30H 30H
N
N
110H
50L
10H110L
C
90L
70H50H
10L
70L
90H
C
30L
N
of mainchain conformations for five of the six CDRs (L1,
L2, L3, H1 and H2). This repertoire of conformations,
commonly called canonical structures, falls into a small
number of discrete structural classes. The various genetic
mechanisms that produce the more diverse H3 regions re-
sult in loops with a wide range of sequences and lengths
compared to the other CDRs, and no classification system
for this loop has yet been defined. In general for the CDR
loops, the particular conformation adopted is mainly deter-
mined by a few key residues within the CDR and in the
conserved b -sheet framework. For Fv4155, CDRs L1, L2
and L3 (of the light chain) and H1 (of the heavy chain),
belong to classes 4, 1, 1 and 1, respectively [20]. Interest-
ingly, these four loops belong to the same canonical struc-
ture groups as those of the antifluorescein Fab 4-4-20
complex [22], which shares an overall 69% sequence iden-
tity with Fv4155. CDR H2, however, differs in that in
Fv4155 it is two residues shorter than in 4-4-20 placing the
former in class 3 and the latter in class 4.
There are no direct interactions between CDR L1 and
the ligand, and the CDR L2 loop is too far from the lig-
and to contribute to the binding pocket. This has been
observed in many other antibody structures, where CDR
L2 does not play a major role in ligand binding [23,24].
CDR L2 contains a type I ¢ b turn [25,26] which places
Val51L in the unusual gamma region of the Ramachan-
dran plot [27] with f =67° and y =–52°, the only disallowed
mainchain conformation in the structure. For a non-
glycine residue this is a sterically unfavourable conforma-
tion, but a valine residue with this conformation has also
been observed at this position in other antibody structures
[2,28–30]. In the case of Fv4155, the only direct light
chain contribution to ligand binding is from CDR L3.
Sidechains of both Ser91L and Leu96L form part of the
ligand binding pocket, whilst Val94L and Pro95L come
within 4 Å of the ligand (Figure 3). An oxygen atom O19,
of the steroid ring D makes a hydrogen bond to the main-
chain nitrogen of Leu96L.
The heavy chain CDR H1 is involved in binding the lig-
and mainly through the interaction of two tyrosine resi-
dues: Tyr32H forms the end of the binding pocket, and
Tyr33H packs next to the sugar ring. CDR H2 provides
the hydrophobic residues that form the side of the binding
cleft, but makes no hydrogen bonds. Residue Ala50H is in
van der Waals contact with C18 of the steroid, while
Leu47H and Ala49H pack against rings B and C. Tyr58H
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Table 1
Crystallisation conditions and crystal parameters.
El3G-I El3G-II E3G-I
Space group P32 P4212 P4212
Cell dimensions (Å) 53.6, 53.6, 83.8 89.9, 89.9, 59.9 90.0, 90.0, 59.6
Asymmetric unit 1 molecule 1 molecule 1 molecule
Solvent content (%) 60.8 48.1 48.0
Mother liquor
drop 1 m l of 5–6 mg ml–1 protein 1 m l of 5–6 mg ml–1 protein 1 m l of 5–6 mg ml–1 protein
and 1 m l of reservoir solution and 1 m l of reservoir solution and 1 m l of reservoir solution
reservoir 0.1M Na acetate, 0.2 M Zn acetate, 0.2 M Zn acetate,
0.05 M Tris/HCl and 15% (w/v) 0.1M Na cacodylate and 18% (w/v) 0.1M Na cacodylate and 18% (w/v)
PEG 4000 PEG 8000 PEG 8000
pH 8.5 7.0 7.0
Table 2
Root mean square deviation between complexes.
Fitting FR Ca atoms* (Å)
Fitting all Ca atoms (Å) Fitting all atoms (Å)
Light and light and heavy deviation for steroid
Light chain Heavy chain heavy chains chains ligand only
El3G-I vs El3G-II 0.240 0.310 0.344 0.459† 0.152
El3G-I vs E3G-I 0.240 0.307 0.343 0.464† 0.364
El3G-II vs E3G-I 0.090 0.079 0.091 0.168 0.327
*The conserved b -sheet framework (FR) consists of VL residues 4–7,
11–13, 19–25, 33–38, 45–48, 62–66, 70–75, 85–90, 97–105 and
VH residues 4–7, 10–12, 18–24, 34–39, 46–49, 67–71, 77–82,
89–94 and 102–110. †Fitting of the El3G-I light chain does not
include the residue 113L at the C terminus as this is not present in the
model.
forms part of the cavity wall stacking against the cyclopen-
tane ring D of the steroid. The type of residue at position
71H has been suggested to determine the conformation of
the H2 loop [31]. In Fv4155, the large residue at this posi-
tion, Arg71H, together with the four-residue turn of H2
(residues 52a–55) corresponds to the canonical class 3, in
line with previous observations. The arginine sidechain is
buried between CDRs H1 and H2, forming hydrogen
bonds with both loops through the mainchain carbonyl
oxygens of Asn52H, Phe29H and Tyr32H.
CDR H3 is a ten-residue twisted loop, that is positioned
on the opposite side of the steroid from CDRs H1 and H2.
Analysis of a number of antibody structures has shown
that CDR H3 has prominent roles both in ligand binding
and in formation of the VL-VH interface [18]. For Fv4155,
the CDR H3 alone accounts for 45.5% (323Å2) of the
buried surface area of the heavy chain upon Fv formation.
Leu95H and Asn96H lie at the end of the cavity wall next
to the sugar ring, with Tyr97H packing perpendicular to
it. The aromatic ring of Tyr100H is stacked against the
hydrophobic rings A and B of the steroid. The overall
heavy chain sequence of Fv4155 is unusual, compared to
other previously determined antibody structures, with sev-
eral rarely observed substitutions in the framework regions
[16]. These substitutions produce local structural changes
to accommodate their respective sidechains, although no
obvious roles in either ligand binding or VL–VH domain
interactions can be attributed to them.
CDR H3 conformation
The conformation of CDR H3 is such that most of the
binding cleft lies between it and the other heavy chain
loops. In a survey of known antibody–antigen complex
structures involving small ligands, peptides and haptens,
several were found to CDR H3 in a similar conformation
[6,32,33]. In varying degrees, all these complexes show the
ligand bound in a site generated primarily from the CDRs
of the heavy chain. The contribution of an induced fit
mechanism in antibody–antigen interactions has frequently
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Figure 3
Comparison of the two steroid hormone
binding sites of the Fv fragment, Fv4155. (a)
Stereoview of the antigen-binding site,
highlighting the narrow cleft in which E3G is
bound and the packing of surrounding
tyrosine residues. Residues from the heavy
chain are shown in green; residues from the
light chain are in purple. (b) Comparison of
the conformation of the Fv4155–E3G and
Fv4155–El3G complexes after superposition
of  the conserved framework residues.
Fv4155–E3G is coloured as in (a) and
Fv4155–El3G is shown in yellow. (Figures
were generated using the program
MIDASPLUS [53].)
been discussed [30,34], and large movements of CDRs
accompanying antigen binding have been observed (for
reviews see [23,24,34,35]). It is interesting to note that
BV04-01, an anti-DNA antibody, exhibits large CDR move-
ments, as it shares sequence identities of 86% and 56%
with the light and heavy chains of Fv4155, respectively.
Without knowledge of the free Fv4155 structure, the pos-
sibility that the H3 loop has undergone a large movement
from its native state cannot be ruled out. The extensive
binding of the ligand by the heavy chain alone, opens up
the possibility of creating a functional single variable bind-
ing domain, as observed in the camelid heavy chain im-
munoglobulin VH domain [36]. 
The binding pocket
The El3G and E3G ligands bind in very similar orienta-
tions, lying in a long, deep cleft lined primarily with
hydrophobic residues (Figure 3a). For all three complexes,
approximately 87% (338–350Å2) of the surface area of the
steroid hormones is buried (Table 3). The surface area of
Fv4155 buried upon binding varies from 398–438 Å2 with
the light chain contributing 21.2% and 18.9% of the
Fv–ligand interface and the heavy chain contributing
78.8% and 81.1% for El3G and E3G, respectively. Both
hormones bind with the steroid inserted into a narrow hy-
drophobic cleft, and make a series of identical hydrogen
bonds from the hydroxyl around the sugar ring (Table 4).
The orientation of the ligand is such that the rings of the
steroid nucleus lie approximately parallel to the interface
between the VL and VH domain. Other hydrogen bonds
involve an ordered network of water molecules, but of the
four direct hydrogen bonds between the protein and the
ligand only one is made to the light chain (Table 4).
As reported for many other antibody structures, numer-
ous aromatic residues surround the antigen-binding site.
These residues contribute significantly to ligand binding
as a consequence of their large hydrophobic surfaces, high
polarizabilities (for greater contribution to van der Waals
interactions), ability to hydrogen bond (through aromatic
rings or polar sidechain atoms), and importantly, because
of their few degrees of conformational freedom (reduced
loss of conformational entropy upon complexation). In
Fv4155, five tyrosine residues line the sides of the binding
cleft, stacking next to either the hydrophobic rings of the
steroid or the sugar ring. These residues alone contribute
over 47% of the total buried surface area of the antibody–
ligand interface. The conformation of the binding site for
both steroids is essentially identical with no significant
changes in any residues involved in forming the cleft.
The cleft can be considered in several sections, each com-
plementary to the different components of the steroid
hormone ligand (Figure 4); the cleft is approximately 23 Å
long and 11 Å deep. The antigen–antibody interfaces are
mostly tightly packed, but include several ordered water
molecules. The sugar ring is stacked in a narrow cleft be-
tween the sidechains of Tyr33H and Tyr97H, and makes
three hydrogen bonds to the polypeptide mainchain. Rings
A and B of the steroid are tightly sandwiched between
Leu95H and the sidechain of Tyr100H (with the steroid a
face presented towards Tyr100H), while rings C and D lie
in a more open cavity partly occupied by ordered water
molecules. The orientation of the steroid nucleus is such
that in all three complexes studied here, O19 makes a
single direct hydrogen bond to the mainchain amide of
Leu96L, in addition to interactions with water molecules.
Differences in binding affinity
The affinity constant of Fv4155 for El3G is approximately
107 l mol–1, with a tenfold increase for the E3G ligand.
The lack of conformational change observed in Fv4155
upon binding the two analogues is not surprising, as the
difference between the two analogues is a single hydroxyl
group on the D ring of the El3G. The difference electron-
density map, calculated with amplitudes (FoE3G–FoEl3G)
and phases a El3G from the model of El3G-II, shows only a
large negative peak at the hydroxyl oxygen O21, and
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Table 3
Surface area (Å2) buried by the ligand–Fv4155 interface for the different complexes.
Complexes El3G-I El3G-II E3G-I
CDR L1 0.0 0.0 0.0
CDR L2 0.0 0.0 0.0
CDR L3 87.2 93.1 78.0
CDR H1 84.1 88.6 85.2
CDR H2 58.9 67.4 60.7
CDR H3 151.3 174.5 171.3
FR2-Leu47H* 16.7 14.9 18.0
Total Fv4155 surface 398.2 438.51 413.2
Steroid hormone ligand† 341.0 (84.9) 350.4 (87.3) 338.0 (87.3)
Buried surface areas were calculated with the program MS [48] using
a probe radius of 1.6 Å and van der Waals radii from Gelin and Karplus
[49]. *This is the only framework residue buried at the ligand–Fv4155
interface. †The values in parentheses are the percentages of the total
surface area of the ligands buried for each complex.
peaks indicating a shift of ring D for the two ligands, when
contoured at 4 rms electron density (Figure 5a). No differ-
ence density can be seen for the Fv itself, but there are
clear difference peaks in the ordered solvent around ring D
of the two ligands. An additional water molecule is present
in the El3G complex (lower left in Figure 5a), and two
neighbouring water molecules move aside to accommodate
it. The difference in binding affinities for El3G and E3G,
therefore seem to be due to differences in the ligand–
protein interactions and subtle changes in the solvation.
Superimposing the two crystal forms of Fv4155–El3G
gives an rms difference of 0.15Å in the ligand position
(Table 2). When fitting E3G-I and El3G-II, however, the
rms difference between corresponding ligand atoms is
slightly higher at 0.33Å, a result of the difference in the
steroid orientation (Figure 3b). The tight binding of the
sugar and steroid ring A within a narrow cleft prevents any
movement in this region, and the changes are concentrated
in rings B, C and D. For El3G, ring B has a twisted 7b ,8b -
sofa conformation (as compared to the 8b -sofa conforma-
tion of ring B for E3G) with both C7 and C8 lying above
the least-squares plane through C5, C6, C9 and C10. This
conformation results in the movement of the cyclopentane
ring D away from the plane of rings A and B, and also away
from the sidechain of Val94L. The conformation differs
from two structure determinations of estriol by Cooper et
al. [37], which showed ring B to be in either a half chair or a
sofa conformation. The Fobs difference electron-density
map around ring B of the two steroid hormones provides
direct evidence for the changes in the conformation of the
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Table 4
Hydrogen bonds in the Fv4155–ligand complexes.
Distances (Å)
Ligand Fv4155 El3G-I El3G-II E3G-I
O19 Leu96L N 2.98 3.07 3.01
O8¢ Tyr33H N 3.10 2.76 2.77
O8¢ Leu95H O 2.47 2.66 2.55
O9¢ Thr31H O 2.32 2.47 2.56
O19 Wat372L 3.26 2.70 3.50
O21 Wat336L 2.77 *
O21 Wat391H 2.72 *
O7¢ Wat344H 3.20 3.30
O9¢ Wat330H 2.80 2.79
O9¢ Wat349H 3.20 3.22
O10¢ Wat349H 2.95 2.95
O10¢ Wat370H 3.01 2.88 3.36
O11¢ Wat388H 3.14 3.09
O11¢ Wat344H 2.53 2.62
O11¢ Wat393H 2.85 3.14
O12¢ Wat359H 2.84 2.72
Hydrogen-bond distances were calculated using the program
CONTACTS [42] with a maximum distance cut-off of 3.5Å and defined
according to the criteria of Baker and Hubbard [50]; values not given
correspond to missing water molecules in the refined structure. The
increase in ordered solvent molecules for both the El3G-II and E3G-I
complexes is a result of the higher resolution data obtained and the
cryogenic temperature used during data collection. *O21 is the extra
hydroxyl oxygen which is not present in the E3G ligand.
Figure 4
Surface representation of Fv4155–E3G displaying the
complementarity between the steroid hormone and the antibody
fragment. The heavy chain is shown in green and the light chain in
purple. The bound E3G molecule is shown as a skeletal representation
with van der Waals radii shown as white dots. (Figure was generated
using the program GRASP [54].)
rings (Figure 5a). The twist in E13G relieves the close con-
tacts between O21 of El3G, and both the C
g 1 and Cg 2
methyl groups of Val94L. If a model of El3G [37] without
this twist is fitted onto E3G in the Fv4155–E3G complex,
the distances between O21 of El3G and Val94L C
g 1 and
C
g 2 would be unfavourably short, 3.07Å and 2.82Å, respec-
tively. Distortions of the steroid nucleus can be gauged by
the calculation of the dihedral angles at the ring junction of
the steroid nucleus. For both El3G and E3G, deviations
from previously reported related steroid structures [38]
were small. A difference of 10°, however, was observed for
the dihedral angle between the least squares planes B and
B–C of El3G (planes B and B–C are defined in [38]). This
value can be used to gauge the distortion of the steroid
nucleus. The conformation adopted by the unliganded
El3G is not known, but if the twisted conformation is not
favoured this distortion could partially explain the lower
binding affinity of El3G with respect to E3G.
The critical role of water molecules in protein structure
and function is well known [39]. The observation of an
extensive network of ordered solvent molecules around
the binding sites of the two complexes provides an oppor-
tunity to study the effect of subtle rearrangements in the
water network as a result of small changes within the ligand.
The bound network of water molecules for the complexes
is virtually identical throughout most of the binding site,
but differs around the D ring of the ligand. For Fv4155–
El3G, the electron density shows three water molecules
(compared to two for the Fv4155–E3G complex) located in
a small hydrophobic cavity between the light chain residue
Val94L and the ligand. Some entropic cost must be asso-
ciated with the binding of these three water molecules to
the protein. The low temperature factors associated with
these three water molecules (10–27Å2) show that they are
more ordered than the two water molecules found in the
same region of the Fv4155–E3G complex (27Å and 32Å2).
Therefore, the entropic penalty in immobilising these three
well ordered water molecules, compared to the two in the
Fv4155–E3G complex, is presumably higher. Despite the
enthalpy gain that would result from the extra water-
mediated hydrogen bond observed in the Fv4155–El3G
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Figure 5
Electron density for the steroid nucleus in the
binding site. (a) Stereoview difference
electron-density map calculated with
amplitudes (FoE3G–FoEl3G) and phases a El3G
from the model of El3G-II showing the
changes in the water conformations within the
small cavity around Val94L between the two
ligands. The El3G model is shown in yellow,
and E3G is shown in standard colours. Water
molecules in E3G-I are shown as white
spheres; water molecules in EI3G-II are
shown as yellow spheres. The positive and
negative electron density is shown in magenta
and cyan, respectively, electron density is
contoured at 4 rms. (b) Stereoview 2Fo–Fc
electron-density map for E3G-I. The quality
and resolution of the final 2Fo–Fc electron-
density map is shown around ring D of the
steroid ligand at the binding site. The electron
density is contoured at 1.5 rms. The single
water molecule not situated in the electron
density, has a high B factor (57 Å2) but there
is density when contoured at a lower value of
0.9 rms. (Figures were generated using the
program O [55].)
complex, the binding affinity of Fv4155 for El3G is lower
than for E3G. This suggests that the contribution of these
changes in solvation, and the resultant entropic cost of the
ordered water molecule within the small hydrophobic cav-
ity of Fv4155–El3G, may be a vital component in deter-
mining the fine specificity of the antibody.
Changes in binding affinities may also originate from dif-
ferences in hydrogen bonding between the two steroids
and the protein. Table 4 lists the hydrogen bonds ob-
served between the ligands, the protein and the water
molecules in the different crystals. The twisted conforma-
tion of steroid ring B of El3G results in slightly poorer
hydrogen-bond geometry between the O19 hydroxyl group
and the mainchain amide nitrogen of Leu96L, when com-
pared to the O19 ketone group of the E3G structure. Both
the hydroxyl and ketone groups at this position for El3G
and E3G are completely buried upon antibody binding. In
addition, for the El3G complex, the desolvation and burial
of 79% (15Å2) of the O21 hydroxyl group solvent-accessi-
ble surface area into a largely hydrophobic environment
must be energetically unfavourable.  It appears that it is a
subtle combination of slightly less favourable hydrogen-
bond geometry, burial of the O21 hydroxyl group in a hy-
drophobic environment, solvent rearrangement and a
steric interaction with Val94L that blocks the end of the
cleft, which result in El3G having a lower binding affinity
than E3G. This suggests that although the interactions
with  CDR L3 of the light chain are few, they may be crit-
ical in  determining the fine specificity of binding.
Comparisons of antisteroid antibody structures
Several other crystal structures of antisteroid antibody–
antigen complexes have been determined: the antibody
DB3 in complex with progesterone and related steroids
[1,2], and the antidigoxin antibodies 26-10 [7] and 40-50
[6]. 26-10 has been studied as a complex with digoxin,
while 40-50 has been studied as a complex with the close-
ly related ouabain. These ligands, like E3G and El3G,
consist of a steroid backbone with a sugar attached to ring
A, but they also have a lactone moiety attached to the
steroid ring D. The orientations of bound digoxin and
ouabain are perpendicular to those of the E3G and El3G
in the Fv4155 complexes. In the antidigoxin complexes,
the ligand interacts primarily with the antibody heavy
chain via their lactone and steroid moieties, and are ori-
ented such that the carbohydrate groups are exposed to
the solvent. This is in contrast to the Fv4155 complexes,
where the carbohydrate group plays an important role in
binding. In this case the glucuronic sugar makes three
hydrogen bonds to Fv4155, compared to the limited inter-
actions observed between the sugar moieties and the
antidigoxin antibodies.
Fv4155 and DB3 share the same CDR canonical struc-
tures, and in both cases the ligand is bound in a narrow
hydrophobic cleft. The steroid rings of both complexes
lie in the same region of the binding cleft but are rotated
by about 140° with respect to each other. This observed
difference results in the D ring of E3G and El3G occupy-
ing the same part of the cleft in Fv4155 as the A ring of
progesterone and its related derivatives in DB3. The dif-
ferences between the D ring conformations of E3G and
El3G, however, are smaller than those between the two
distinct A ring conformations observed for the proges-
terone derivative ligands of DB3. To accommodate the
sugar ring of the steroid hormone ligand, the binding cleft
of Fv4155 extends far beyond that seen in the DB3 struc-
ture. The cleft of the DB3 antibody would be of insuffi-
cient length to accommodate the El3G and E3G steroid
hormones, owing to the presence of the Tyr97H side-
chain on CDR H3. The equivalent Tyr97H in Fv4155,
however, adopts a different rotamer position placing the
aromatic ring parallel to the sugar moiety, resulting in a
larger binding cleft than that observed for DB3. The
insertion of the sugar is also facilitated by a shift of ap-
proximately 2.5 Å by CDR H3 away from the ligand,
when compared to the superimposed DB3, causing the
CDRs H1 and H3 to lie further apart. Inhibition studies
of DB3 using various progesterone derivatives have shown
substitutions in the D ring to severely inhibit binding [2].
Although the D ring of E3G and El3G is bound in a dif-
ferent part of the Fv4155 binding cleft, as compared to
the superimposed progesterone–DB3 structure, the change
in binding affinity for Fv4155 as a result of the minor
chemical differences in the D ring of E3G and El3G, shows
that this ring is also very important for the specificity of
Fv4155 binding. Comparison of the bound and free con-
formations of DB3 shows a closing of the binding site
created by the movement of the indole ring of Trp100H.
For the Fv4155 complex, this position is occupied by a
tyrosine residue. In absence of the structure of the free
Fv4155, it can only be speculated whether this residue
will have a similar role in the closing of the binding site
when the ligand is not bound.
Biological implications
The ability of an antibody to recognise an antigen with
high binding affinity and specificity can be exploited to
elucidate the physical and chemical nature of protein–
ligand interactions. The study of a series of antibody
complexes with structurally and chemically distinct lig-
ands has been used to increase our understanding of
these interactions at the molecular level [2]. Investiga-
tion into the cross-reactivity of antibodies, however, has
not yet advanced sufficiently to allow prediction of which
antigens will bind and which will not. Structural studies
of the binding of multiple ligands by a single antibody
show that small but significant changes often occur
upon binding. Understanding these subtle changes is the
key to elucidating the underlying principles of antibody
cross-reactivity.
Research Article  Monoclonal antibody fragment Fv4155 Trinh et al. 945
Monitoring of the levels of steroid glucuronides in serial
samples of early morning urine (EMU) to predict the
fertile period in the female menstrual cycle has previ-
ously been investigated [10–12]. The work presented
here, shows how two of these steroid hormone ligands,
estrone b -D-glucuronide (E3G) and estriol 3-(b -D-glu-
curonide) (El3G), that differ by a single hydroxyl group
bind to a given antibody Fv fragment, Fv4155, with a
tenfold difference in their dissociation constant Kd. The
D ring of the ligand was shown to adopt a different con-
formation in the two complexes and distinct differences
in the network of ordered solvent molecules arise as a
direct result of burying these different conformations of
the steroid moiety. The solvent reordering reflects the
changes in the D ring and the solvent molecules act to
maximise the complementarity of both the physical and
chemical properties of the interacting surface of the
binding site. The difference in entropic penalties in-
curred in immobilising these water molecules, in addi-
tion to small changes in the bound steroid moiety,
determines the overall specificity of this antibody frag-
ment. These findings have revealed that differences in
the binding affinities for the steroid hormone–Fv4155
complexes originate from small structural changes in the
ligands, rather than from changes in the Fv molecule,
and emphasises the importance of structured water mol-
ecules in biological recognition.
Materials and methods
Expression of Fv4155-myc
The gene fragments encoding the Fv region of anti-E3G Fv4155 with
myc tail were cloned into the plasmid pUC19 and expressed in
Escherichia coli strain JM 109. The cells were grown in 2 · TY contain-
ing 100 m g ml–1 ampicillin and 55 mM glucose at 37°C for 17 h. The
biomass was harvested by centrifugation at 2000 g for 30 min at 20°C
(SORVALL RC 5B, GSA rotor). The supernatant was discarded and
the cells resuspended in half of the original volume of 2 · TY without
glucose. Expression of the Fv was induced with 0.5 mM isopropyl-b -D-
thiogalactopyranoside (IPTG), and the cells were incubated at 25°C
with shaking for 24 h. The cells were harvested by centrifugation at
10 000 g for 30 min at 4°C. The supernatant was clarified by 0.2 m m fil-
tration. The product was recovered from the cells by osmotic shock in
20% (w/v) sucrose in 200 mM Tris-HCl buffer (pH 6.8) containing
1 mM EDTA. Cellular debris was removed by centrifugation (as before)
followed by 0.2 m m filtration.
Detecting and quantitating Fv4155 was based on an indirect antibody
enzyme-linked immunosorbent assay (ELISA) procedure [40]. Micro-
titre plates were sensitised with estrone-3 glucuronide/ovalbumin (Col-
worth House, Unilever, UK) conjugate at 2 m g ml–1 in carbonate buffer
pH 9.6 for 1 h at 37°C. Affinity purified control samples of Fv4155, neg-
ative controls, supernatant and periplasmic samples were diluted in
phosphate-buffered saline containing 0.15% (v/v) tween-20  (PBS-T).
Samples of 100 m l volume were dispensed in duplicate wells and incu-
bated at 25°C for 1 h. The monoclonal tracer antibody was mouse
antimyc used at 1 m g ml–1 in PBS-T and dispensed at 100 m l volume to
each well with incubation as before. This was followed with goat anti-
mouse alkaline phosphatase conjugate (Zymed, UK) diluted in PBS-T
to 1 m g ml–1 concentration and dispensed at 100 m l volume to each
well, and incubated for 1 h. All steps were followed by washing in PBS-
T to remove any unbound material. The substrate was p-nitrophenyl
phosphate 1 mg ml–1 in 1 M diethanolamine buffer, pH 9.8, containing
1 mM MgCl2, dispensed at 100 m l volume to each well. Plates were
incubated until colour development had occurred sufficiently, and then
read at 405 nm in a microplate reader (Bio-Rad, Model 3550).
Purification
An affinity matrix was prepared by covalently coupling estrone (Sigma
Chemical Co., UK) to epoxy-activated sepharose (Pharmacia Biotech
Ltd., UK), and supernatants and lysates were loaded onto a column
containing this material at 2 ml min–1. Columns were washed to base
line with phosphate-buffered saline containing 0.1% sodium azide
(PBS-A), and Fv was eluted with an antigen analogue with high cross-
reactivity, or antigen at 0.2 mg ml–1 in PBS-A. The peak was desalted
using Sephadex G-25 M (Pharmacia Biotech Ltd., UK), or dialysis in
50 mM Tris-HCl buffer, pH 7.2, then concentrated to 6 mg ml–1 by cen-
trifugation at 6000 g at 4°C (SOLVAL RC 5B, SS-34 rotor). Purity of
the resulting antibody fraction was assessed by sodium dodecyl sul-
phate gel electrophoresis.
Crystallisation
Crystals of the Fv4155–E3G and Fv4155–El3G complexes were
grown at room temperature by hanging-drop vapour diffusion methods.
The crystallisation conditions and crystal parameters are shown in
Table 1. Two crystal forms, El3G-I and El3G-II, of the Fv4155–El3G
complex were obtained, that diffracted to resolutions of 2.5 Å and
2.1 Å, respectively. Crystals of the Fv4155–E3G complex (E3G-I) are
isomorphous with crystal form El3G-II, and also diffracted to 2.1 Å.
Data collection and processing
Data for all three complexes were recorded with an Raxis IIc image-
plate detector mounted on a Rigaku RU200 rotating anode X-ray gen-
erator, and equipped with an Oxford Cryosystem ‘Cryostream’ crystal
cooler. X-ray radiation was produced at CuK
a
wavelength using a
300 m m focus at 50 kV, 100 mA. The radiation was monochromatised
and focused using MSC double focusing mirrors. The 2.5 Å data from a
El3G-I crystal were collected at room temperature, while both the 2.1 Å
data sets were collected at 100K. Diffraction data were integrated with
MOSFLM [41] and reduced using programs from the CCP4 program
suite [42]. Data collection statistics are summarised in Table 5.
Molecular replacement, model building and refinement
Molecular replacement calculations were carried out using data from
8.0–3.0 Å resolution with the program suite AMoRe [42]. The search
model was based on an autoantibody structure which binds single-
stranded DNA [43]. Its light chain sequence showed the highest homo-
logy to Fv4155 in a comparison of 32 antibody sequences. The heavy
chains also have moderate sequence homology as determined by
AbMTM (Oxford Molecular Inc.) [44]. To avoid model bias, the following
changes were made to the search model:  all CDR regions according
to Kabat [16] were deleted, and all nonconserved residues changed to
alanines.
El3G-I form
As the El3G trigonal data were collected first the search model
described above was used to solve this structure. The R factor and
correlation coefficient for the best solution from AMoRe were 48.2%
and 37.1%, respectively. The search model was subjected to further
rigid-body refinement with the program X-PLOR [45], with the VH and
VL treated as two independent rigid bodies, and progressively higher
resolution data included in five steps from 6 Å to 2.5 Å giving a final
R factor of 42.6%.
The atomic model was built into a 2Fo–Fc map phased from the rigid-
body model using the graphics program FRODO [46]. Further refine-
ment included three rounds of X-PLOR simulated annealing, and
repetitive rounds of model building and least-squares refinement using
PROLSQ [42]. After all the CDR loop residues had been built into the
model, waters were placed where there was good electron density and
hydrogen-bonding geometry.
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El3G-II and E3G-I forms
The refined structure of El3G-I was used as the search model for the
molecular replacement into the El3G-II data. To reduce bias all CDR
loops, as defined by Kabat, were again deleted from the search model.
The R factor and correlation coefficient from the best solution in
AMoRe were 43.5% and 57.1%, respectively. The R factor was a little
higher than expected, probably due to the deletion of 18% of the
residues from the search model. Using the structure of El3G-I as a
guide, the missing CDR residues were built back into the new El3G-II
model during cycles of model building and refinement with PROLSQ
[42]. Further refinement was carried out using PROLSQ, with the addi-
tion of water molecules playing a more important role in lowering the R
factor in the low temperature structure. A final round of refinement,
using a bulk solvent correction, was carried out in X-PLOR [45].
The final refined structure of the El3G-II structure was then used as the
search model in the molecular replacement solution for the E3G-I data.
As the structures are in the same space group, the whole of the anti-
body fragment including the CDR loops was used as the search model,
only omitting the steroid ligand. The R factor and correlation coefficient
were 27.1% and 81.9%, respectively. The model was then refined in
the same way as for El3G. The quality of the final 2Fo–Fc electron-
density map of the Fv4155–E3G structure is shown in Figure 5b. The
final refined Fv models, which lacked the steroid hormone ligands were
analysed with simulated annealing omit maps calculated using X-PLOR
[45], which confirmed the correct location and orientation of the
steroid in the binding site.
Analysis and final model parameters
Refinement of the El3G-II structure revealed a sequencing error at
Thr96H. Checks on the DNA sequencing gels revealed that the
residue was in fact an asparagine. Further sequencing checks indi-
cated another error: Leu111H should have been valine.
The refined model of the El3G-I complex contains 231 residues out of
the 232 in the sequence (the residue at the C terminus of the light chain
is missing) and includes 64 water molecules. The conventional R factor
is 17.6% for all the data between 10.0 Å and 2.5 Å. No crystallographic
free R factor was calculated for this complex. Final refinement of this
structure was aided by comparison with the 2.1 Å structures, especially
in regions of poor density. 
Both the El3G-II and E3G-I complexes contain all 232 residues with
182 and 186 water molecules, respectively. The R factor and free R
factor are 18.7% and 27.1%, for the El3G complex, and 17.8% and
24.7% for the E3G complex, using all data from 10 Å–2.1 Å. The rms
deviation from ideality for bond distances is 0.011 Å, for both com-
plexes, and for angle distances is 0.037 Å and 0.038 Å for El3G-II and
E3G-I, respectively. The mainchain dihedral angles for the majority of
the residues in the refined models of all three complexes lie in the most
favoured regions of the Ramachandran plot (83%–95%) [27]. Only
one amino acid residue (Val51L) lies within the unfavourable areas
defined by the program PROCHECK [47] in all three structures; this
residue lies in a type I¢ b turn. Refinement statistics for all three com-
plexes are summarised in Table 5.
Accession numbers
Coordinates and structure factors for the three complexes El3G-I,
El3G-II and E3G-I have been deposited in the Brookhaven Protein Data
Bank with the PDB accessions codes 1bfv, 2bfv and 1cfv, respectively.
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